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Keratinocytes are an important component of the skin
immune system, and keratinocyte-derived cytokines
control the function of Langerhans cells.We previously
showed that CX-659S, a novel diaminouracil derivative,
had an inhibitory e¡ect on hapten-induced contact hy-
persensitivity reaction in mice. In this study, we investi-
gated the mechanism by which CX-659S elicits its
inhibitory e¡ect. CX-659S inhibited the expressions of
CD80 and CD86, but not that of CD54, on Langerhans
cells in epidermal cell suspensions. Exogenous granulo-
cyte-macrophage colony-stimulating factor restored
the CX-659S-induced inhibition of CD80 and CD86 ex-
pressions of Langerhans cells. The production of inter-
leukin-2 from allogeneic T cells was also inhibited
when the cells were stimulated with CX-659S-treated
epidermal cells, and this inhibition was suppressed by
the addition of granulocyte-macrophage colony-stimu-
lating factor during CX-659S treatment. As CX-659S
signi¢cantly inhibited production of granulocyte-
macrophage colony-stimulating factor from keratino-
cytes, CX-659S was thought to indirectly a¡ect
Langerhans cells by inhibiting the function of keratino-
cytes. These e¡ects of CX-659S were preceded by
blockade of the phosphorylation of extracellular-sig-
nal-regulated kinase 1/2 and their direct activators,
mitogen-activated protein kinase/extracellular-signal-
regulated kinase 1/2 (MEK1/2), but not p38 mitogen-
activated protein kinase or inhibitory nuclear factor
jBa, in keratinocytes. Furthermore, a speci¢c MEK1/2
inhibitor, U0126, mimicked the e¡ect of CX-659S.
CX-659S, a keratinocyte-response modi¢er, would be
an e¡ective therapeutic compound to inhibit contact
hypersensitivity reaction, its action mechanism being
di¡erent from those of other immunosuppressive
agents such as glucocorticosteroids or cyclosporine A.
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K
eratinocytes (KC) are the main constituent of the
epidermis and, by producing a broad repertoire of
cytokines and chemokines, control allergic and in-
£ammatory responses and help to maintain the
homeostasis of skin (Bos and Kapsenberg, 1993).
Under normal conditions, most cytokines are not synthesized or
remain in the cytoplasm, but external stimuli, such as trauma,
bacterial infections, chemical substances, and ultraviolet irradia-
tion, induce the production and release of these cytokines from
KC (Lee et al, 1997; Steinho¡ et al, 2001). These stimulations trig-
ger the activation of nuclear factor kB (NF-kB) and mitogen-
activated protein kinases (MAPK), such as p38 MAPK, extracel-
lular-signal-regulated kinase (Erk), and c-Jun N-terminal kinase,
in KC, and these molecules are known to regulate cytokine
production, proliferation, di¡erentiation, apoptosis, and migra-
tion of KC (Peus et al, 1999; Abeyama et al, 2000; Kippenberger
et al, 2000; Pfundt et al, 2001; Chouinard et al, 2002).
Langerhans cells (LC) originate from bone marrow and reside
in the epidermis as antigen-presenting cells (Katz et al, 1979). LC
capture exogenous antigens and move into the regional lymph
nodes to present antigens to naive T cells (Kripke et al, 1990; Ban-
chereau et al, 2000). Thus, contact hypersensitivity reaction
(CHR) can be controlled by inhibiting the function of LC and
T cells. Steroids and other immunosuppressive drugs actually in-
hibit the function of both LC and T cells (Furue and Katz, 1988;
1989; Salgado et al, 1999). KC and LC directly interact with each
other (Tang et al, 1993) and KC-derived cytokines such as granu-
locyte-macrophage colony-stimulating factor (GM-CSF), inter-
leukin-1 (IL-1), and tumor necrosis factor a (TNF-a) are
essential to maintain viability and mediate functional maturation
of LC (Witmer-Pack et al, 1987; Heu£er et al, 1988). A drug that
has the capacity to inhibit the function of KC could therefore be
used to inhibit the CHR and other cutaneous in£ammation.
We have recently found that a novel diaminouracil derivative,
CX-659S ((S)-6-amino-5-(6-hydroxy-2,5,7,8-tetramethylchroman-
2-carboxamido)-3-methyl-1-phenyl-2,4(1H,3H)-pyrimidi-nedione),
had an antioxidative property and exhibited an inhibitory
activity against hapten-induced acute and chronic CHR (Goto
et al, 2000; 2002; Tobe et al, 2000; Inoue et al, 2002). In this study,
we investigated the e¡ect of CX-659S on epidermal cells.
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CX-659S blocked the phosphorylation of Erk1/2 and MAPK/Erk
kinase 1/2 (MEK1/2), leading to inhibition of production of
GM-CSF from KC and the maturation of LC.
MATERIALS AND METHODS
Subjects Six to 8-wk-old female BALB/c and C3H/HeN mice were
purchased from Charles River (Tokyo, Japan). The protocol was approved
by the Committee of Ethics on Animal Experiments in the Graduate
School of Medical Sciences, Kyushu University.
Reagents RPMI-1640 supplemented with 10% heat-inactivated fetal
bovine serum (FBS), 1% penicillinstreptomycin (all Gibco-BRL, Grand
Island, NY), and 50 mM 2-mercaptoethanol (Sigma, St. Louis, MO) were
used as complete medium. CX-659S, synthesized by Sumika Fine
Chemicals (Osaka, Japan), was dissolved in dimethyl sulfoxide (DMSO;
Nacalai Tesque, Kyoto, Japan) at a concentration of 100 mM and further
diluted in complete medium. The ¢nal concentration of DMSO never
exceeded 0.5% and had no inhibitory e¡ect in the following experiments.
Recombinant murine GM-CSF and IL-1bwere purchased from Genzyme
(Cambridge, MA). U0126 and picryl chloride (PC) were purchased from
Calbiochem (Dermstadt, Germany) and Sigma, respectively.
Antibodies Fluorescein isothiocyanate (FITC) conjugated rat anti-
mouse CD86 antibody (clone GL1), FITC-conjugated hamster antimouse
CD54 antibody (clone 3E2), FITC-conjugated hamster antimouse
CD80 antibody (clone 16-10A1), and phycoerythrin-conjugated mouse
antimouse Ia antibody (I-Ak; clone 11-5.2) were purchased from
PharMingen (San Diego, CA). FITC-conjugated rat IgG2a,k, FITC-
conjugated hamster IgG, and phycoerythrin-conjugated mouse IgG2b,k (all
from PharMingen) were used as isotype-matched controls.
Preparation of epidermal cell suspension Ear skin specimens from
C3H/HeN mice were treated with 0.5% type IX trypsin (Sigma) in
phosphate-bu¡ered saline (PBS) for 30 min at 371C to separate the
epidermis from the dermal connective tissue. The epidermal sheets were
agitated gently in complete medium with 0.05% deoxyribonuclease I
(Sigma), and epidermal cell suspension was obtained after ¢ltration
through sterile nylon mesh.
Flow cytometric analysis Suspensions of epidermal cells obtained
from C3H/HeN mice were cultured with CX-659S (0^500 mM) in the
presence or absence of 20 ng per ml of GM-CSF for 72 h at 371C. The
nonadherent cell population, containing the vast majority of LC, was
then recovered and washed twice with cold bu¡er [PBS containing 2%
FBS and 0.1% sodium azide (Sigma)]. Subsequent stainings with labeled
antibodies or isotype-matched controls were performed for 30 min on
ice. Stained cells were washed twice and resuspended in cold bu¡er
containing 10 mg per ml 7-amino-actinomycin D (Sigma) and analyzed
with a £ow cytometer (Coulter, Tokyo, Japan). Ia-positive cells in the
nonadherent cells were regarded as LC, and the expressions of CD80,
CD86, and CD54 on LC were analyzed.
Assay of il-2 production from allogeneic T cells Spleen cells from
BALB/c mice were passed through a nylon wool column. More than 90%
of the collected cells were CD3-positive T cells (data not shown).
Suspensions of epidermal cells from C3H/HeN mice were treated with
CX-659S (0^500 mM) in the presence or absence of 20 ng per ml of GM-
CSF for 24 h at 371C. CX-659S-treated epidermal cells were collected and
washed twice and then cocultured with allogeneic T cells from BALB/c
mice for 3 d. The ratio of LC in the epidermal cell suspensions to
allogeneic T cells was adjusted to 1:100, and the amount of IL-2 in the
culture supernatant was measured using a murine IL-2 enzyme-linked
immunosorbent assay (ELISA) kit (BioSource, Camarillo, CA) according
to the manufacturer’s protocol. T cells were also stimulated with 20 ng per
ml of phorbol 12-myristate 13-acetate (PMA; Sigma) and 200 ng per ml of
ionomycin (Sigma) in the presence of CX-659S (0^500 mM) for 24 h, and
the amount of IL-2 in each supernatant was measured in the same way.
Cytokine ELISA A suspension of epidermal cells (5105 per ml)
obtained from C3H/HeN mice was cultured overnight in complete
medium, and the nonadherent cells were extensively washed out. The
remaining adherent cells did not express major histocompatibility
complex (MHC) class II, but were positive for cytokeratin (data not
shown). These cells were thus regarded as being mainly KC. KC were
further cultured with increasing concentrations of CX-659S (0^500 mM)
in the presence or absence of 100 ng per ml of IL-1b for 48 h at 371C. The
amounts of GM-CSF, TNF-a, and IL-1a in each supernatant were
measured using respective ELISA kits (BioSource and Endogen,Woburn,
MA) according to the manufacturers’ protocols.
Western blot analysis KC were prepared as described above. After
pretreatment with 500 mM CX-659S for 90 min, cells were stimulated
with 100 ng per ml of IL-1b for 5^30 min. The cells were then washed
twice with cold PBS and lyzed with 100 ml of lysis bu¡er [50 mM
TrisHCl (pH 7.4), 1% Triton X-100, 150 mM NaCl, 10% glycerol,
2 mM ethylenediamine tetraacetic acid, 2 mM ethyleneglycol-bis
(b-aminoethyl ether)-N,N,N0,N0-tetraacetic acid, 40 mM b-glycero-
phosphate, 50 mM NaF, 10 mM sodium pyrophosphate, 200 mM sodium
orthovanadate, 0.3 mM leupeptin, 1 mM pepstatin A, 1 mM phenyl-
methylsulfonyl £uoride, and 100 nM okadaic acid]. The homogenates
were centrifuged at 15,000 rpm for 15 min at 41C. Five to 10 mg of cell
lysates were electrophoresed on 4%^12% gradient Bis-Tris gels and
transferred to nitrocellulose membranes. After blocking with 5% fat-free
dried milk, membranes were incubated with either antiphosphorylated
p38 MAPK, Erk1/2, MEK1/2, or NF-kB inhibitor (IkBa) antibodies (Cell
Signaling, Beverly, MA) for 12 h at 41C and then with horseradish-
peroxidase-labeled goat antirabbit IgG (Bio-Rad, Hercules, CA) for
90 min. Immunoreactive bands were visualized by ECL detection reagent
(Amersham, Piscataway, NJ). After stripping, the membranes were
reprobed with either antitotal p38 MAPK, Erk1/2, or IkBa antibodies
(Cell Signaling) as respective loading controls.
Inhibition of the MEK1/2ERK1/2 pathway Suspensions of
epidermal cells were prepared and treated with U0126 (0^50 mM) for
72 h, and the expressions of CD86 on Ia-positive LC were analyzed using
a £ow cytometer as described above. KCwere also prepared and cultured in
the presence of U0126 (0^50 mM), and the amount of GM-CSF in the
supernatant was measured by ELISA. The e¡ect of U0126 on PC-induced
CHR in BALB/c mice was also analyzed as previously described (Goto et al,
2000). Five mice in a group were sensitized by applying 0.1 ml of 7% PC
solution in acetone to the shaved abdomen. Seven days later, the mice were
challenged by applying 0.02 ml of 1% PC solution in acetone to the left
ear. U0126 (0^100 mg per ear) or CX-659S (0^1000 mg per ear) dissolved
in DMSO was painted on the left ear 1 h before the challenge. The ear
thickness was measured with a calibrated digital thickness gauge
(Mitutoyo, Tokyo, Japan) before and 24 h after the challenge, and the
di¡erence in thickness was calculated.
Statistical analysis Student’s t test was used to analyze the results, and a
p-value of less than 0.05 was considered to be statistically signi¢cant.
RESULTS
CX-659S inhibits the upregulation of CD80 and CD86 on
LC and exogenous GM-CSF reverts it The expressions of
MHC class II, costimulatory molecules, and adhesion molecules
on LC are upregulated by culturing epidermal cell suspensions
in vitro for a few days, which leads to the functional maturation
of LC (Witmer-Pack et al, 1987). KC-derived GM-CSF is one of
the main mediators of this maturation (Salgado et al, 1999). Thus
we ¢rst carried out an experiment to determine whether CX-
659S a¡ected the expressions of surface molecules on LC. After
culturing suspensions of epidermal cells with CX-659S (0^500
mM), the expressions of CD86, CD80, and CD54 on Ia-positive
cell population were analyzed using a £ow cytometer. First, the
toxicity of CX-659S was examined by the use of 7-amino-
actinomycin D, which discriminates between viable, apoptotic,
and necrotic cells, and it was found that CX-659S up to a
concentration of 500 mM did not a¡ect the viability of
epidermal cells (data not shown). CX-659S inhibited the
upregulation of CD86 (Fig 1A) and CD80 (Fig 1B), but not
CD54 (Fig 1C), on Ia-positive LC in a concentration-dependent
manner, whereas exogenous GM-CSF restored the expressions of
these surface molecules. The upregulation of Ia was also
moderately suppressed by CX-659S, but the restorative e¡ect of
GM-CSF on the expression of Ia was only marginal (Fig 1D).
CX-659S-pretreated epidermal cells inhibit production of
IL-2 from allogeneic T cells As CX-659S inhibited the
expressions of CD86 and CD80 on LC, we next checked the
potency of CX-659S-treated epidermal cells for stimulation of
production of IL-2 from allogeneic T cells. After pretreatment
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with CX-659S for 24 h, LC-containing epidermal cells were
cocultured with allogeneic T cells for 72 h. CX-659S-treated
epidermal cells had less potency for stimulation of production of
IL-2 fromTcells than did untreated epidermal cells. On the other
hand, epidermal cells treated with CX-659S in the presence
of exogenous GM-CSF had a capacity for stimulation of
production of IL-2 from T cells that was equal to that of
untreated epidermal cells (Fig 2A). These results correlated with
Figure1. E¡ect of CX-659S on the expression of surface molecules on LC. Suspensions of epidermal cells were treated with increasing concentra-
tions of CX-659S (0^500 mM) for 72 h in the presence (white circles) or absence (black circles) of GM-CSF (20 ng per ml). The expressions of surface molecules
on Ia-positive LC were analyzed. The mean £uorescence intensity of each molecule was measured using a £ow cytometer, and percentages of mean £uor-
escence intensity levels compared with those of respective control conditions (CX-659S 0 mM) were calculated. Data are means7SEM of four independent
experiments. npo0.05 compared with respective control conditions.
Figure 2. E¡ect of CX-659S on production of IL-2 from allogeneic Tcells. (A) Suspensions of epidermal cells were treated with CX-659S (0^500
mM) for 24 h in the presence (white circles) or absence (black circles) of GM-CSF (20 ng per ml) and then cells were washed out. CX-659S-treated epidermal
cells were cocultured with allogeneic T cells for 72 h and the amount of IL-2 in each culture supernatant was measured. Data are means7SEM of three
independent experiments. npo0.05. (B) T cells were also stimulated with PMA and ionomycin for 24 h in the presence or absence of CX-659S and the
amount of IL-2 was measured. Data are means7SEM of three independent experiments.
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the e¡ect of CX-659S on the expressions of CD80 and CD86 on
LC. To see the direct e¡ect of CX-659S on T cells, T cells were
also stimulated with PMA and ionomycin in the presence or
absence of CX-659S. Interestingly, CX-659S per se did not a¡ect
production of IL-2 from PMA and ionomycin-stimulated T cells
(Fig 2B).
CX-659S inhibits production of GM-CSF from KC As the
e¡ect of CX-659S on LC in an epidermal cell suspension was
found to be dependent on GM-CSF, we next examined the
direct e¡ects of CX-659S on the production of GM-CSF, TNF-
a, and IL-1a from KC. All cytokines that we selected were
spontaneously produced by KC and IL-1b enhanced their
production. CX-659S inhibited both spontaneous and IL-1b-
induced production of GM-CSF in a concentration-dependent
manner (Fig 3A), whereas production of TNF-a was only
inhibited by the highest concentration of CX-659S tested
(Fig 3B) and production of IL-1a was not signi¢cantly
inhibited (Fig 3C).
CX-659S inhibits the phosphorylation of ERK1/2 and
MEK1/2, but not p38 MAPK or IjBa, in KC NF-kB and
MAPKs regulate the production of many cytokines (Ghosh et al,
1998; Dong et al, 2002), and IL-1b can activate these molecules
(O’Neill and Dinarello, 2000). We next examined the e¡ect
of CX-659S on the phosphorylation of the IkBa, p38
MAPK, Erk1/2, and MEK1/2 in KC. KC were left untreated
or stimulated with IL-1b for the indicated periods of time
in the presence or absence of CX-659S, and cellular lysates
were subjected to western blotting analyses. Only the
phosphorylation of Erk1/2 and their direct activators, MEK1/2,
was inhibited by CX-659S in both unstimulated and IL-
1b-stimulated KC, whereas CX-659S did not a¡ect the
phosphorylation of p38 MAPK or IkBa (Fig 4). Therefore, CX-
659S was thought to inhibit production of GM-CSF from KC by
blocking the MEK1/2Erk1/2 pathway.
A speci¢c MEK1/2 inhibitor U0126 has similar e¡ects to
CX-659S Finally, we carried out an experiment to determine
whether a speci¢c inhibitor of the Erk1/2 pathway mimicked
the e¡ects of CX-659S. U0126 is a speci¢c inhibitor of MEK1/2
(Favata et al, 1998). Similar to the e¡ect of CX-659S, U0126 also
inhibited the upregulation of CD86 on LC in the epidermal cell
suspensions, and this inhibition was reverted by exogenous GM-
CSF. Compared with CX-659S, the upregulation of Ia was not
a¡ected by U0126 (Fig 5A). In addition, U0126 suppressed both
Figure 3. CX-659S inhibits production of GM-CSF from KC. Epi-
dermal KC were prepared and cultured for 48 h with CX-659S (0^500
mM) in the presence or absence of IL-1b (100 ng per ml). The amounts of
GM-CSF (A), TNF-a (B), and IL-1a (C) in each supernatant were mea-
sured. Data are means7SEM of three independent experiments. npo0.05.
Figure 4. CX-659S inhibits the phosphorylation of Erk1/2 and MEK1/2. KCwere pretreated with CX-659S (500 mM) for 90 min and then stimulated
with IL-1b (100 ng per ml) for the indicated periods of time. Cellular lysates were subjected to western blot analysis for Erk1/2, MEK1/2, p38 MAPK, and
IkBa. Data are representative of three independent experiments.
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spontaneous and IL-1b-induced production of GM-CSF from
KC (Fig 5B) as previously shown in mast cells and smooth
muscle cells (Dumitru et al, 2000; Hallsworth et al, 2001). We
previously showed that CX-659S had an inhibitory activity
against hapten-induced CHR (Goto et al, 2000). We then
checked the e¡ect of U0126 on PC-induced CHR in mice.
Topically applied U0126 as well as CX-659S inhibited PC-
induced ear swelling in mice in a concentration-dependent
manner (Fig 5C). These data further con¢rmed that the e¡ect of
CX-659S was attributed to blockade of the MEK1/2Erk1/2
pathway.
DISCUSSION
KC-derived GM-CSF is a crucial cytokine for LC. LC express
GM-CSF receptors, and GM-CSF upregulates the expressions of
CD80 and CD86 on LC in vitro and enhances the immunostimu-
latory function of LC (Witmer-Pack et al, 1987; Heu£er et al, 1988;
Salgado et al, 1999). GM-CSF is also known to be an indispensa-
ble factor for the generation of dendritic cells from precursor cells
in murine bone marrow (Inaba et al, 1992). CX-659S inhibited
the upregulation of CD80 and CD86 on LC, leading to inhibi-
tion of production of IL-2 from allogeneic T cells. The immu-
noinhibitory e¡ects of CX-659S were thought to practically
result from inhibition of production of GM-CSF from KC,
because the impaired maturation of LC was overcome by the
addition of exogenous GM-CSF the expression of MHC
class II.
As we used nonadherent cells in epidermal cell suspensions to
stimulate allogeneic T cells, dendritic epidermal T cells may a¡ect
the result of production of IL-2.We con¢rmed that the amount
of IL-2 from allogeneic T cells was not altered after depletion of
dendritic epidermal T cells from epidermal cell suspensions (data
not shown) by anti-Thy-1 antibody and complement treatment as
previously reported (Rouabhia et al, 1993).We therefore concluded
that production of IL-2 from allogeneic T cells was most a¡ected
by LC in epidermal cell suspensions.
Erk1/2 are MAPK that control cell survival and di¡erentiation
(Pearson et al, 2001; Dong et al, 2002). Erk1/2 have also been
shown to regulate the production of GM-CSF and TNF-a in
some types of cells, such as mast cells and smooth muscle cells
(Dumitru et al, 2000; Kimata et al, 2000; Hallsworth et al, 2001).
As CX-659S inhibited the phosphorylation of Erk1/2 and MEK1/
2 and U0126, a speci¢c MEK1/2 inhibitor, had similar e¡ects to
those of CX-659S, blockade of the MEK1/2Erk1/2 pathway
may be critical for the biologic action of CX-659S. As U0126
had no e¡ect on MHC class II, CX-659S may a¡ect another mo-
lecule that regulates the expression of MHC class II. U0126 in-
hibited not only the production of GM-CSF from KC and the
upregulation of CD86 on LC in vitro, but also PC-induced
CHR in mice in vivo. Though the 50% inhibitory concentration
of U0126 was even lower than that of CX-659S, it seems di⁄cult
to clinically apply U0126 because of its instability in solution
(Duncia et al, 1998). Stable compounds that can block the MEK1/
2Erk1/2 pathway, such as CX-659S, are therefore promising for
clinical trial.
Grabbe et al showed that removal of LC by steroid application
or ultraviolet B irradiation after hapten sensitization resulted in
the enhancement of CHR. These authors suggested that resident
LC were not the relevant antigen-presenting cells in the e¡ector
phase of CHR (Grabbe et al, 1995). Thus, CX-659S or U0126 may
preferentially a¡ect the a¡erent phase of CHR by inhibiting the
antigen-presenting capacity of LC, and it would be of interest to
check the activity of these compounds after removal of LC.
KC are known to express both type I IL-1 receptor (IL-1R1)
and IL-1R2, and IL-1R1 is active in signal transduction (Rausch-
mayr et al, 1997). IL-1 activates IL-1R1, and that signal is trans-
mitted through a pathway remarkably similar to that of Toll-
like receptor, ¢nally leading to the phosphorylation of MAPK
and NF-kB (O’Neill and Dinearello, 2000). Although Erk1/2 are
activated in the IL-1R/Toll-like receptor pathway (Kawai et al,
1999), the pathway from IL-1R1 to Erk1/2 has not been comple-
tely elucidated. Erk1/2 are activated by the dual phosphorylation
of both threonine and tyrosine residues in the Thr-Glu-Tyr mo-
tif, which is induced by two speci¢c MAPK kinases, MEK1 and
MEK2 (Zheng and Guan, 1993). The Raf family of protein ki-
nases is known to directly phosphorylate MEK1/2 in the epider-
mal growth factor receptor pathway (Pearson et al, 2001), but we
could not detect any induction of the phosphorylation of c-Raf
in IL-1b-stimulated murine KC (our unpublished data).
Although further investigations are needed to identify the target
molecules of CX-659S, our data suggest that CX-659S prevents
the phosphorylation of Erk1/2 by inhibiting MEK1/2 or another
Figure 5. The speci¢c MEK1/2 inhibitor U0126 mimics the e¡ect of
CX-659S. (A) Suspensions of epidermal cells were cultured with U0126
(0^50 mM) in the presence or absence of GM-CSF (20 ng per ml) for 72
h, and the expression of CD86 on Ia-positive LC was analyzed. Data are
representative of three independent experiments. (B) KC were cultured
with U0126 (0^50 mM) in the presence or absence of IL-1b (100 ng per
ml) for 48 h, and the amount of GM-CSF in each supernatant was mea-
sured. Data are means7SEM of three independent experiments. (C) Sen-
sitized mice were challenged by 1% PC solution in acetone to the left ear.
U0126 (0^100 mg per ear) or CX-659S (0^1000 mg per ear) was painted 1 h
before the challenge. The ear thickness was measured before and 24 h after
the challenge, and the di¡erence in thickness was calculated. Data are
means7SEM of ¢ve mice. npo0.05.
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molecule(s) between IL-1R1 and MEK1/2, and CX-659S could
be a useful tool to further dissect the signaling pathway from
IL-1R1 to Erk1/2.
Compared with other immunosuppressive agents such as glu-
cocorticosteroids or cyclosporine A, CX-659S exerts its immu-
noinhibitory e¡ects by di¡erent mechanisms because it did not
directly inhibit production of IL-2 from T cells stimulated with
PMA and ionomycin. Glucocorticosteroids elicit their immuno-
suppressive e¡ects by inhibiting several transcription factors,
including NF-kB, as well as MAPK (Auphan et al, 1995; Schein-
man et al, 1995; Pelaia et al, 2001), whereas cyclosporine A inhibits
the activity of calcineurin and then nuclear factor of activated T
cells as well as p38 MAPK and c-Jun N-terminal kinase (Matsuda
and Koyasu, 2000). Both immunosuppressants directly inhibit the
antigen-presenting capacity of LC (Furue and Katz, 1988; 1989;
Salgado et al, 1999). Blockade of the activation of p38 MAPK or
NF-kB is known to correlate with inhibition of dendritic cell
maturation (Verhasselt et al, 1999; Arrighi et al, 2001; Uchi et al,
2002), whereas that of Erk1/2 does not (Puig-Kroger et al, 2001;
Yanagawa et al, 2002). Our results are in accordance with these
reports because CX-659S did not directly inhibit the phenotypic
and functional maturation of LC. In keeping with this notion,
we con¢rmed that CX-659S did not inhibit either IL-1b- or li-
popolysaccharide-induced upregulation of costimulatory mole-
cules on bone-marrow-derived dendritic cells from C3H/HeN
mice, even though CX-659S inhibited the phosphorylation of
Erk1/2 (our unpublished data).
We previously showed that CX-659S had an inhibitory activ-
ity against PC- or oxazolone-induced CHR in mice and guinea
pigs (Goto et al, 2000; Inoue et al, 2002).We ¢rst speculated that
CX-659S had a direct immunosuppressive e¡ect on LC and T
cells. This was not the case, however. CX-659S is likely to exert
its in vivo immunosuppression by inhibiting production of GM-
CSF from KC, leading to subsequent impairment of functional
maturation of LC. It has recently been reported that KC-derived
GM-CSF is signi¢cantly increased in atopic subjects (Pastore et al,
1997) and that GM-CSF inhibits the production of Th1-inducing
cytokine IL-12 from LC (Tada et al, 2000). These authors specu-
lated that excessive production of GM-CSF from KC might cause
an imbalanced and exaggerated maturation of LC in association
with Th2-dominant immune response in atopic subjects (Pastore
et al, 1997; Tada et al, 2000). The results of this study suggest that
the inhibitor of the MEK1/2Erk1/2 pathway may rather selec-
tively inhibit the spontaneous and IL-1b-induced production of
GM-CSF from KC and that these KC response modi¢ers may be
useful therapeutic agents for CHR and atopic dermatitis.
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